drugset / Trial / NCT00520468
Treatment of Myelodysplastic Syndrome (MDS) With Cytokine-Immunotherapy for Low-Risk MDS
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Objectives: Primary: To evaluate the response rate of total cytokine-immunotherapy for low-risk myelodysplastic syndromes (MDS). Secondary: To evaluate response duration, survival and side effects of the treatment.
Timeline
- Start
- 2004-06
- Primary completion
- 2009-06
- Completion
- 2009-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Cyclosporine | Peptide | 300 mg | Oral |
| Background | G-CSF | Unknown | 300 ug | Subcutaneous |
| Background | Prednisone | Other / unclassified | 60 mg | Oral |
| Background | epoetin alfa | Protein / enzyme biologic | 40000 iu | Subcutaneous |